The global cell culture market is projected to grow at a CAGR of 12% from 2025 to 2030. This growth is driven by increasing ...

Thank you, Operator, and welcome, everyone, to the Nanalysis Scientific’s fourth quarter and full year 2024 conference call.

Besides generics, Dr. Reddy’s has committed a lot of resources to develop its biosimilars as well as new chemical entity business. Biosimilars have been seen as a growth engine for large, capable ...

CEO Gary Guthart quelled concerns of reflexive pricing, with production and manufacturing optimisation a priority instead.

IntroductionIn the fast-evolving landscape of performance enhancement, athletes and bodybuilders are no longer satisfied with ...

Major drugmakers were a standout on a tumultuous day of corporate earnings on Thursday, beating expectations even as they ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

As we stride further into 2025, the pharmacy industry faces a landscape teeming with challenges and opportunities. From tackling drug ...

Read about Merck, EssilorLuxottica, Wuxi Biologics and more in the latest Market Talks covering the Health Care sector.

Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.